Skip to main content

Advertisement

Table 3 Univariate associations between clinical benefit and PFS on anti-EGFR-based clinical trial retreatment

From: Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response

Patient characteristics Clinical benefit PFS
  Total (n) Responded n (%) p Total (n) Progressed (n) Median (95 % CI) p
Response to prior anti-EGFR treatment
  No 50 23 (46) 0.007 52 45 2.50 (1.58, 3.42) 0.064
  Yes 36 27 (75)   37 31 4.90 (3.60, 6.20)  
Interval length between treatments
  < median 42 20 (48) 0.053 44 40 3.20 (1.97, 4.43) 0.286
  ≥ median 44 30 (68)   45 36 4.10 (2.61, 5.59)  
Race/Ethnicity
  Non-White 24 17(71) 0.138 26 22 5.20 (3.94, 6.46) 0.034
  White 62 33(53)   63 54 3.00 (1.92, 4.08)  
Gender        
  Female 43 24 (56) 0.662 44 41 3.80 (2.88, 4.72) 0.323
  Male 43 26 (61)   45 35 3.70 (2.48, 4.92)  
Age
  < 60 years 55 32 (58) 0.992 57 50 3.70 (2.91, 4.49) 0.619
  ≥ 60 years 31 18 (58)   32 26 3.80 (2.03, 5.57)  
PS (ECOG)
  0 32 20 (63) 0.528 35 28 3.80 (2.67, 4.93) 0.286
  ≥ 1 54 30 (56)   54 48 3.60 (2.08, 5.12)  
Number of metastatic sites
  < 3 42 26 (62) 0.489 42 35 4.50 (3.03, 5.97) 0.077
  ≥ 3 44 24 (55)   47 41 3.20 (1.92, 4.48)  
Serum albumin
  Normal 69 40 (58) 0.949 72 61 3.80 (3.18, 4.42) 0.920
  Low 17 10 (59)   17 15 3.00 (0.00, 6.77)  
Serum LDH
  Normal 19 9 (47) 0.281 19 15 2.80 (0.37, 5.24) 0.667
  Elevated 67 41(61)   70 61 3.80 (3.05, 4.55)  
RMH score
  0 or 1 43 25 (58) 1.000 43 35 3.70 (2.00, 5.40) 0.408
  2 or 3 43 25 (58)   46 41 3.80 (2.81, 4.79)